Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sales & Earnings In Brief

This article was originally published in The Tan Sheet

Executive Summary

Pfizer’s divested nutrition unit up 9% in Q1; Church & Dwight battles tough environment, toothbrush recall; Cyvex grows but fish meal trends sink Omega Protein; Reliv pins U.S. turnaround hopes on LunaRich launches.

You may also be interested in...



Nestle Pays Nearly $12 Bil. For Desirable Pfizer Nutrition Portfolio

Nestle’s $11.85 billion acquisition of Pfizer’s pediatric nutritionals business came in above or at the upper end of most analysts’ expectations. With the deal, Nestle keeps the portfolio – projected to generate $2.4 billion in 2012 sales – away from rivals Danone and Mead Johnson.

Omega Protein Diversifies In Nutritionals, But Draws Short-Term Doubts

Omega Protein acquired Cyvex Nutrition and InCon Processing in the past 15 months to enter the dietary supplement market and vertically integrate its omega-3 fish oil supply chain. The firm gained from a one-time settlement payment in 2011, but saw underlying earnings fall.

Sales & Earnings In Brief

Bayer credits Aspirin, Aleve for consumer gains; Vitamin Shoppe thinking small with new stores; DSM nutrition grows on volume, Martek performance; more Sales & Earnings In Brief.

Topics

Related Companies

UsernamePublicRestriction

Register

PS105737

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel